Ben Fidler

Virginia

Senior Editor at BioPharma Dive

Senior Editor at Industry Dive

Biotech Journalist; Senior Editor, BioPharma Dive. Former Deputy Biotech Editor, Xconomy.

Featured in: Favicon

biopharmadive.com Favicon

xconomy.com Favicon

healthcaredive.com Favicon

newsbreak.com Favicon

supplychaindive.com Favicon

k12dive.com Favicon

highereddive.com Favicon

medtechdive.com Favicon

bankingdive.com Favicon

substack.com + 7 more

Articles

Merck, Daiichi pull approval application for ADC in lung cancer

1 week ago | biopharmadive.com | Ben Fidler

Merck & Co. and Daiichi Sankyo have withdrawn an approval application in the U.S. for a lung cancer drug at the center of a multibillion-dollar alliance the companies formed two years ago. In a short statement Thursday, the companies said they’ve pulled a Food and Drug Administration submission for an experimental therapy known as patritumab deruxtecan.
Pfizer buys into PD-1/VEGF competition with 3SBio deal

2 weeks ago | biopharmadive.com | Ben Fidler

This audio is auto-generated. Please let us know if you have feedback. Pfizer is wagering billions of dollars on a new kind of cancer immunotherapy, agreeing Monday to license a type of dual-targeting medicine that’s emerged as a must-have for drugmakers in oncology. The pharmaceutical giant will pay biotechnology company 3SBio $1.25 billion upfront for rights outside of China to a therapy dubbed SSGJ-707.
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

3 weeks ago | biopharmadive.com | Ben Fidler

Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Travere Therapeutics, Allogene and Kyverna Therapeutics that you may have missed. A federal jury has found Amgen liable for violating antitrust and tort laws by using “bundled rebates” to give its cholesterol drug Repatha preferred market positioning over Regeneron Pharmaceuticals'rival Praluent.
A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

3 weeks ago | biopharmadive.com | Ben Fidler

A group of scientists successfully made a bespoke gene editing medicine for a critically ill baby in just a few months, suggesting CRISPR technology could be used to quickly develop personalized therapies for an array of ultra-rare diseases. Study results published in The New England Journal of Medicine and presented at a medical meeting Thursday reveal that a treatment tailored to an infant with a deadly metabolic disorder was safely administered.
iTeos, GSK to shelve TIGIT drug after study setback

3 weeks ago | biopharmadive.com | Ben Fidler

Dive Brief:A two-drug regimen involving an experimental cancer immunotherapy from iTeos Therapeutics and GSK didn’t significantly delay tumor progression in a Phase 2 trial, leading the companies to end development and terminate the collaboration they formed around the drug four years ago.
Abeona sells speedy drug review voucher for $155M

3 weeks ago | biopharmadive.com | Ben Fidler

Abeona Therapeutics has quickly cashed in on a recent drug approval, agreeing on Monday to sell a so-called priority review voucher awarded by the Food and Drug Administration to an undisclosed buyer for $155 million. Abeona earned the voucher two weeks ago, when the FDA cleared a cell therapy called Zevaskyn for a form of epidermoloysis bullosa, a rare skin condition.
Abeona sells speedy drug review voucher for $155M

3 weeks ago | finance.yahoo.com | Ben Fidler

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Abeona Therapeutics has quickly cashed in on a recent drug approval, agreeing on Monday to sell a so-called priority review voucher awarded by the Food and Drug Administration to an undisclosed buyer for $155 million.
4 more biotechs cut staff amid market tumult

1 month ago | biopharmadive.com | Ben Fidler

Four biotechnology companies are laying off staff in the latest examples of cutbacks in a sector struggling to hold its footing amid financial market turmoil. On Thursday, Vor Bio, Korro Bio, Rallybio and Insitro all revealed plans to cut at least a fifth of their respective workforces. For Vor, the developer of a type of CRISPR-aided stem cell transplant, those cuts were particularly steep, involving 95% of its employees and a wind-down of its clinical and manufacturing operations.
Haya banks $65M to scour the ‘dark genome’ for new drugs

1 month ago | biopharmadive.com | Ben Fidler

Scientists long believed the human genome consisted mostly of useless DNA. These sequences, after all, aren’t translated into proteins, making them appear as bits of genetic material with no biological purpose. They were often referred to as “junk.”Accumulating academic research over the last decade or so has proven otherwise. That “junk” is transcribed into so-called long non-coding RNAs, which are key cogs of the molecular machinery that switches genes on or off.
Prasad’s FDA appointment pressures cell and gene therapy stocks

1 month ago | pharmavoice.com | Ben Fidler

This audio is auto-generated. Please let us know if you have feedback. Shares in more than a dozen gene and cell therapy developers tumbled by double digits Wednesday after a well-known critic of the speedy approval paths their treatments often rely on was named to lead the FDA office that regulates them. Dr. Vinay Prasad, an oncologist and contrarian voice in clinical research, was hired by FDA Commissioner Martin Makary to run the Center for Biologics Evaluation and Research.